Diabetes drug shows promise in slowing Parkinson's progression
NCT ID NCT03439943
Summary
This study tested whether lixisenatide, a drug used for type 2 diabetes, could slow the worsening of movement problems in people with early Parkinson's disease. 156 participants received either the drug or a placebo as a daily injection for one year, in addition to their standard Parkinson's medications. The main goal was to see if the drug could modify the underlying disease process, not just treat symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Toulouse
Toulouse, 31000, France
-
Creteil- Henri Mondor Hospital
Créteil, France
-
Pitié Salpêtrière Hospital
Paris, France
-
University Hospital of Amiens
Amiens, France
-
University Hospital of Besancon
Besançon, France
-
University Hospital of Bordeaux
Bordeaux, France
-
University Hospital of Caen
Caen, France
-
University Hospital of Clermont-Ferrand
Clermont-Ferrand, France
-
University Hospital of Lille
Lille, France
-
University Hospital of Limoges
Limoges, France
-
University Hospital of Lyon
Lyon, France
-
University Hospital of Marseille
Marseille, France
-
University Hospital of Montpellier
Montpellier, France
-
University Hospital of Nancy
Nancy, France
-
University Hospital of Nantes
Nantes, France
-
University Hospital of Nice
Nice, France
-
University Hospital of Poitiers
Poitiers, France
-
University Hospital of Rennes
Rennes, France
-
University Hospital of Rouen
Rouen, France
-
University Hospital of Strasbourg
Strasbourg, France
Conditions
Explore the condition pages connected to this study.